An interventional study of Albenza 200Mg Tablet in Toxocara Infection, sponsored by Pham Ngoc Thach University of Medicine. Status unknown. Open to participants aged 3 Years to 15 Years. Per ClinicalTrials.gov, last updated 2022-04-20.
Sponsored by Pham Ngoc Thach University of Medicine · Not applicable, Interventional, and Treatment
This study consists 2 phases. The first phase will conduct a cross-sectional study to determine the infection rate of Toxocariasis larvae, describe the clinical and paraclinical characteristics, identify risk factors related to Toxocariasis larva infection. The second phase will conduct an interventional study to evaluate the effectiveness and factors related to the Albendazole treatment on pupils infected with Toxocariasis larvae in Ho Chi Minh City.
This study includes 2 phases below:
Phase 1: Cross-sectional study Sample population: total 960 pupils aged 3-15 years old from public kindergartens, primary schools, and secondary schools in Ho Chi Minh City.
Data collection will be conducted following stages below:
Taking blood for testing:
Phase 2: Interventional study Children infected with Toxocariasis larvae were recruited from the cross-sectional survey based on the results of positive ELISA test for Toxocariasis, with or without increased BCAT and IgE, history and clinical symptoms.
Sample size was calculated based on the research results of Fernando (treatment within 3 months), about 146 children will be recruited about 146 children, intervention with Albendazole treatment on these children is sufficient.
Evaluation after intervention: Children after being diagnosed will be invited into intervention with Albendazole according to the protocol, continued to follow up after 1 month and 6 months in most cases.
* Within the scope of this topic, we evaluate the cure based on standards from the disease under the guidance of the Vietnam Ministry of Health in 2020
Data collection process includes the steps of intervention by the research team below:
Standard operating procedures Examination procedure The research team coordinated with the school administration and the school health department to organize a visit at the school.
Examination of children is carried out by pediatricians of Pham Ngoc Thach University of Medicine with seniority, prestige, and practice certificates, undergraduate and postgraduate teaching jobs at Children's Hospital 2.
Procedures for taking blood samples, storing and transporting samples and handling accidents Sample Place of implementation: At the school of the child selected for the study. Test type: Complete blood count (TPTTBM), AST-ALT, Urea Creatinine, IgE, ELISA Performer: Pediatric nurse with seniority working at Children's Hospital 2, with good practice and professional certificates.
Blood volume: 4ml (divided into 3 specialized tubes: 0.5ml for BM; 1.5ml for urea-creatinine, AST-ALT, IgE; 2ml for ELISA) Storage and transportation Blood samples are stored at 4 - 8ºC in a dedicated shipping container and transported to Children's Hospital 2 laboratory 2 hours before the time of sampling according to the correct procedure Handling accidents Equip shockproof box and appropriate on-site first aid equipment, handle according to the protocol of the Ministry of Health, transfer the child to the nearest medical facility.
Procedure for performing the test Place of implementation: Laboratory of Children's Hospital 2 (hematology, biochemistry, microbiological diagnosis) Technique of ELISA test to find antibodies to Toxocariasis larvae. Test principles
Sample collection and preparation Serum or plasma is stored at 2-8 0C for five days. Serum can be kept longer if stored at -20ºC for a long time. Do not freeze whole blood samples. Do not heat the sample and avoid freezing and thawing many times.
Read the results ELISA reader: reads zero with air. Set up a dual wavelength readout at 450/620-650 nm.
Positive: Absorbance reading is more than 0.3 OD units. Negative: Absorbance reading is less than 0.3 OD units. Information of the Toxocara ELISA Kit used for testing
Procedure for monitoring and taking care of children during treatment During the time the intervention group takes albedazol, the research team will coordinate with the school health department to monitor the children's clinical manifestations, call parents and guardians to assess unwanted effects of medication, reminders of treatment adherence, and preventive measures.
Procedure for recording side effects, adverse events, and adverse event handling
Ethics This study was carried out through clinical examination, blood collection for routine tests and oral Albedazol intervention. We only conduct tests and drug interventions with the consent of the family and the school (signed the agreement through the consent form).
During the research, children are always monitored and evaluated for complications as well as side effects of drugs; If any, they will be consulted or treated according to the guidance of the Ministry of Health and the treatment costs will be covered from the project's budget.
This study was conducted with the approval of the Biomedical Research Ethics Council of Pham Ngoc Thach University of Medicine Ho Chi Minh City.
Funding: Department of Science and Technology of Ho Chi Minh City, Vietnam.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's planned enrollment of 960 is above the median of 120 across 4,200 interventional studies indexed under Infections.
Browse Infections studies →Pham Ngoc Thach University of Medicine is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria for phase 1 study:
Inclusion criteria for intervention:
ELISA results according to the specified Kit and read according to optical densities (OD).
Cases of suspected heart, lung, liver, eye damage ... referred to Children's Hospital 2 for examination by specialty and not for intervention.
Exclusion Criteria:
Treatment drugs: Albendazole (Zentel) tablets 200mg, Glaxo Wellcome Production France manufacturer . Dose: 15 mg/kg divided into 2 times/day x 5 days, orally after meals. Procedure: Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days. Limiting reinfection: Advice on preventing reinfection Advice on preventing re-infection according to Vietnam Ministry of Health disease prevention guidelines
Drug: Albenza 200Mg Tablet
Distributing albedazol (Zentel) 200mg at school to parents or guardians, dose 15mg/kg divided into 2 times/day, instructions to take the medicine in full dose, at the right time after meals, for 5 days. Limiting reinfection: Advice on preventing reinfection
Also known as: Zentel
Procedures Guidelines for diagnosis, treatment, and post-treatment follow-up of Toxocariasis larvae
After phase 1, we hope that we can draw a new procedure guideline for the diagnosis and treatment. And after this study is done, the new standard of guidelines for treatment of Toxocariasis infection can be applied for all children hospital in Vietnam.
Time frame: 12 months
Seminars on treatment and follow-up after treatment of toxocariasis
After the phase 1 of the study, we can oganize the seminars based on the knowledge we have reviewed and will discuss about the treatment and follow-up to all the medical doctors who are interested in this topic.
Time frame: 12 months
Pet care consultation club, how to prevent toxocariasis
This club will invite the parents and anyone who care about taking care of animals such as dogs, cats at the family participate in this consultation club to provide information related to Toxocariasis infection and will educate them how to prevent infecting from Toxocariasis for children at home.
Time frame: 12 months
Publishing journal articles
Based on the reviewing the epidemiology and the situation about Toxocariasis in Vietnam, we can publish an article on it. After the phase 1 is done, we can publish the second article and after the phase 2 is done, we can publish the third one.
Time frame: 24 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pham Ngoc Thach University of Medicine